Saturday, November 18, 2023 4:31:27 PM
The 7 MMs defendants said that even if the spoofing allegations were true, they only profited a combined total of about $94,000. However, I am sure that the Judge, Laura Posner, NWBio, shareholders and the investment public know that making a profit was not their main motivation.
Here are some of the primary reasons why these 7 Market Maker defendants having been illegally spoofing NWBO shares for more than 5+ years:
1/4: Thanks for detailed analysis. The 7 MMs defendants say they didn’t profit much from spoofing. But real reasons they spoofed were: (1) keep $NWBO shares trading in a narrow range from $0.42 to $1.10 to prevent or delay a short squeeze for legal shorts & illegal naked shorts, https://t.co/V0vzi98fYt
— ATLnsider (@ATLnsider) November 18, 2023
2/4: and (2): artificially & illegally manipulate $NWBO share price to make it more difficult to raise sufficient capital at fairly valued share prices, without extensive dilution & having to issue more shares than what would be required if shares weren’t illegally manipulated.
— ATLnsider (@ATLnsider) November 18, 2023
3/4: and (3) make it more difficult for $NWBO to raise needed capital at fairly valued share prices to prevent or delay $NWBO from paying all relevant costs to prepare all MAA & BLA regulatory submissions required for #DCVax-L approvals in US, Canada, UK, Germany & rest of EU.
— ATLnsider (@ATLnsider) November 18, 2023
4/4: (4) illegally manipulate $NWBO shares to prevent or delay an uplist from OTC (where it’s easier to legally short & to illegally naked short to NASDAQ, NYSE or AMEX. Illegally manipulating NWBO share price, prevents or delays meeting minimum share price requirement to uplist.
— ATLnsider (@ATLnsider) November 18, 2023
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM

